|
|
 Previous Article | Table of Contents | Next Article 
RAPID COMMUNICATION
Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-Induced Suppression of Immune Surveillance
Andreas Villunger,
Alexander Egle,
Ingrid Marschitz,
Marion Kos,
Günther Böck,
Heinz Ludwig,
Stephan Geley,
Reinhard Kofler, and
Richard Greil
From the Laboratory of Molecular Cytology, the Department of Internal Medicine, University of Innsbruck; the Department of Oncology, Wilhelminen Spital, Vienna; and the Division of Molecular Pathophysiology, the Department of General and Experimental Pathology, University of Innsbruck, Innsbruck, Austria.
The Fas (Apo-1/CD95) ligand (FasL) plays a central role in the elimination of target cells by effector T lymphocytes and in the suppression of cellular immune responses against nonmalignant and malignant cells. We show the expression of FasL on the surface of neoplastic plasma cells. We provide evidence that the FasL is functionally active because five of five neoplastic plasma cell lines tested killed CEM-C7H2 T-acute lymphoblastic leukemia (T-ALL) cells. The effect was mediated via the Fas (Apo-1/CD95) receptor molecule because blocking of Fas on the target cells or the FasL on the tumor cells by receptor- and ligand-specific monoclonal antibodies (MoAbs), respectively, protected T cells from being killed by myeloma cells. In addition, overexpression of the cowpox virus protein CrmA, a molecule with inhibitory potential on caspase-1 and caspase-8, specifically involved in Fas-induced signaling, protected T cells from being destroyed by the neoplastic cells or the agonistic anti-Fas MoAb. The potential of the malignant plasma cells to extinguish target T cells was independent of their own sensitivity to the agonistic anti-Fas MoAb, and FasL-positive (FasL+) CEM-C7H2 T cells were incapable of killing myeloma cells. Our results suggest that tumor cell-induced suppression of the immune system may be exerted via the FasL active on malignant plasma cells. Furthermore, loss of Fas expression or insensitivity to the agonistic anti-Fas MoAb do not seem to be prerequisites for myeloma cells to defeat T cells via Fas/FasL interaction.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 12-20
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Gopalan, A. Litvak, S. Sharma, A. M. Mhashilkar, S. Chada, and R. Ramesh
Activation of the Fas-FasL Signaling Pathway by MDA-7/IL-24 Kills Human Ovarian Cancer Cells
Cancer Res.,
April 15, 2005;
65(8):
3017 - 3024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Bohana-Kashtan and C. I. Civin
Profiling Tumor Counterattack: Do Fas Ligand-Containing Microvesicles Reduce Anticancer Immunity?
Clin. Cancer Res.,
February 1, 2005;
11(3):
968 - 970.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Poulaki, C. S. Mitsiades, C. McMullan, G. Fanourakis, J. Negri, A. Goudopoulou, I. X. Halikias, G. Voutsinas, S. Tseleni-Balafouta, J. W. Miller, et al.
Human Retinoblastoma Cells Are Resistant to Apoptosis Induced by Death Receptors: Role of Caspase-8 Gene Silencing
Invest. Ophthalmol. Vis. Sci.,
January 1, 2005;
46(1):
358 - 366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Bohana-Kashtan and C. I. Civin
Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance
Stem Cells,
November 1, 2004;
22(6):
908 - 924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Greil, G. Anether, K. Johrer, and I. Tinhofer
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
J. Leukoc. Biol.,
September 1, 2003;
74(3):
311 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-i. Fujii, K. Shimizu, F. Koji, and F. Kawano
Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential
J. Leukoc. Biol.,
January 1, 2003;
73(1):
82 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Sapi, W. D. Brown, S. Aschkenazi, C. Lim, A. Munoz, B. M. Kacinski, T. Rutherford, and G. Mor
Regulation of Fas Ligand Expression By Estrogen in Normal Ovary
Reproductive Sciences,
July 1, 2002;
9(4):
243 - 250.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. H. Igney and P. H. Krammer
Immune escape of tumors: apoptosis resistance and tumor counterattack
J. Leukoc. Biol.,
June 1, 2002;
71(6):
907 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. N. Ivanov, M. Krasilnikov, and Z.'e. Ronai
Regulation of Fas Expression by STAT3 and c-Jun Is Mediated by Phosphatidylinositol 3-Kinase-AKT Signaling
J. Biol. Chem.,
February 8, 2002;
277(7):
4932 - 4944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Ni, P. Hazarika, C. Zhang, R. Talpur, and M. Duvic
Fas Ligand Expression by Neoplastic T Lymphocytes Mediates Elimination of CD8+ Cytotoxic T Lymphocytes in Mycosis Fungoides: A Potential Mechanism of Tumor Immune Escape?
Clin. Cancer Res.,
September 1, 2001;
7(9):
2682 - 2692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Silvestris, M. Tucci, P. Cafforio, and F. Dammacco
Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression
Blood,
March 1, 2001;
97(5):
1155 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schmidt, N. Lugering, A. Lugering, H.-G. Pauels, K. Schulze-Osthoff, W. Domschke, and T. Kucharzik
Role of the CD95/CD95 Ligand System in Glucocorticoid-Induced Monocyte Apoptosis
J. Immunol.,
January 15, 2001;
166(2):
1344 - 1351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Mueller and D. W. Scott
Distinct Molecular Mechanisms of Fas Resistance in Murine B Lymphoma Cells
J. Immunol.,
August 15, 2000;
165(4):
1854 - 1862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Costello, F. Mallet, B. Gaugler, D. Sainty, C. Arnoulet, J.-A. Gastaut, and D. Olive
Human Acute Myeloid Leukemia CD34+/CD38- Progenitor Cells Have Decreased Sensitivity to Chemotherapy and Fas-induced Apoptosis, Reduced Immunogenicity, and Impaired Dendritic Cell Transformation Capacities
Cancer Res.,
August 1, 2000;
60(16):
4403 - 4411.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
I TINHOFER, H WYKYPIEL, I MARSCHITZ, T HENN, R GREIL;, M W BENNETT, J O'CONNELL, D ROCHE, C BRADY, J KELLY, et al.
Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway • Reply
Gut,
May 1, 2000;
46(5):
738 - 740.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tinhofer, I. Marschitz, T. Henn, A. Egle, and R. Greil
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma
Blood,
January 15, 2000;
95(2):
610 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Shimizu, A. Fontana, Y. Takeda, H. Yagita, T. Yoshimoto, and A. Matsuzawa
Induction of Antitumor Immunity with Fas/APO-1 Ligand (CD95L)-Transfected Neuroblastoma Neuro-2a Cells
J. Immunol.,
June 15, 1999;
162(12):
7350 - 7357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Strater, S. M. Mariani, H. Walczak, F. G. Rucker, F. Leithauser, P. H. Krammer, and P. Moller
CD95 Ligand (CD95L) in Normal Human Lymphoid Tissues : A Subset of Plasma Cells Are Prominent Producers of CD95L
Am. J. Pathol.,
January 1, 1999;
154(1):
193 - 201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mitsiades, V. Poulaki, V. Kotoula, A. Leone, and M. Tsokos
Fas Ligand Is Present in Tumors of the Ewing's Sarcoma Family and Is Cleaved into a Soluble Form by a Metalloproteinase
Am. J. Pathol.,
December 1, 1998;
153(6):
1947 - 1956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tinhofer, I. Marschitz, M. Kos, T. Henn, A. Egle, A. Villunger, and R. Greil
Differential Sensitivity of CD4+ and CD8+ T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand+ Tumor Cells in B Chronic Lymphocytic Leukemia
Blood,
June 1, 1998;
91(11):
4273 - 4281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
